Faeth Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 27, 2026, 7:33 a.m. ETView on SEC.gov
Departure/appointment of directors or officers
AI summary, unreviewedFaeth Therapeutics Expands Board to Seven, Appoints Oncology Development Executive Adam Schayowitz as Class III Director
8-KSept. 17, 2026, 4:15 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 4, 2026, 7:40 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits